Advanced Enzyme Technologies

Advanced Enzyme Technologies Current Liabilities

The Current Liabilities of Advanced Enzyme Technologies (ADVENZYMES.NS) as of Oct 17, 2026 is 1.07 B INR. In the previous year, Current Liabilities was 1.35 B INR — a change of -20.82% (lower).

Current Liabilities

1.07 BINR

YoY

-20.82%

Last updated:

Current Liabilities of Advanced Enzyme Technologies is 2026 1.07 B INR. Current Liabilities of Advanced Enzyme Technologies was 2025 1.35 B INR. It decreases by -20.82% lower compared to the previous year.

The Advanced Enzyme Technologies Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
738.90 M INR
Jan 1, 2020
756.21 M INR
Jan 1, 2021
766.94 M INR
Jan 1, 2022
520.20 M INR
Jan 1, 2023
613.59 M INR
Jan 1, 2024
1.22 B INR
Jan 1, 2025
1.35 B INR
Jan 1, 2026
1.07 B INR
The Advanced Enzyme Technologies Current Liabilities history
YEARCurrent LiabilitiesYoY
1.07 BINR-20.82%
1.35 BINR+10.14%
1.22 BINR+99.44%
613.59 MINR+17.95%
520.20 MINR-32.17%
766.94 MINR+1.42%
756.21 MINR+2.34%
738.90 MINR-30.28%
1.06 BINR+33.62%
793.14 MINR-36.19%
1.24 BINR-25.95%
1.68 BINR-3.05%
1.73 BINR+28.10%
1.35 BINR+0.88%
1.34 BINR+189.16%
463.26 MINR+9.73%
422.17 MINR+18.54%
356.15 MINR-3.69%
369.80 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Advanced Enzyme Technologies Stock analysis

What does Advanced Enzyme Technologies do? Advanced Enzyme Technologies Ltd is a company based in Thane, India, operating within the Materials sector, specifically in the Chemicals industry. The company focuses on the research, development, manufacture, and sale of enzyme products, employing 338 full-time staff. It completed its initial public offering (IPO) on August 1, 2016. Advanced Enzyme Technologies develops and markets a range of enzyme-based products derived from indigenous sources, including over 68 types of enzymes and probiotics. The company serves various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing, malting, grain processing, protein modification, dairy processing, textile processing, and others. Its product portfolio includes solutions for human nutrition featuring serratiopeptidase, fungal lactase, fungal lipase, and papain; animal nutrition products like DigeGrain X, DigeGrain XL, and DigeGrain M; food processing solutions for dairy and cheese, as well as yeast processing; and non-food applications in textile processing, leather, and biofuels. The company also provides services related to oils and fats processing, including oil extraction and refining. Advanced Enzyme Technologies Ltd maintains a website at https://www.advancedenzymes.com/ for further information about its operations and offerings. Advanced Enzyme Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advanced Enzyme Technologies stock

Current Liabilities of Advanced Enzyme Technologies is 1.07 B INR in 2026.

Current Liabilities of Advanced Enzyme Technologies changed from 1.35 B INR to 1.07 B INR, representing a -20.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Advanced Enzyme Technologies since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Advanced Enzyme Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Advanced Enzyme Technologies

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Advanced Enzyme Technologies